Arch, BN 
ORCID: 0000-0001-6060-8091, Kovacs, D ORCID: 0000-0002-2187-743X, Scott, JT ORCID: 0000-0001-8030-5223, Jones, AP ORCID: 0000-0001-5253-730X, Harrison, EM ORCID: 0000-0002-5018-3066, Rosala-Hallas, A ORCID: 0000-0001-8012-9995, Gamble, CG ORCID: 0000-0002-3021-1955, Openshaw, PJM ORCID: 0000-0002-7220-2555, Baillie, JK ORCID: 0000-0001-5258-793X and Semple, MG ORCID: 0000-0001-9700-0418
(2021)
Evaluation of the effectiveness of remdesivir in severe COVID-19 using observational data from a prospective national cohort study
[Preprint]
Abstract
<h4>Background</h4> Remdesivir has been evaluated in clinical trial populations, but there is a sparsity of evidence evaluating effectiveness in general populations. <h4>Methods</h4> Adults eligible to be treated with remdesivir, requiring oxygen but not ventilated, were identified from UK patients hospitalised with COVID-19. Patients treated with remdesivir within 24h of hospitalisation were compared with propensity-score matched controls; estimates of effectiveness were calculated for short-term outcomes (14-day mortality, 28-day mortality, time-to-recovery among others) using multivariable modelling. <h4>Results</h4> 9,278 out of 39,330 patients satisfied eligibility criteria. 1,549 patients were identified as ‘treated’ and matched with 4,964 controls. Patients were 62% male, mean (SD) age 63.1 (15.6) years, 80% ‘White’ ethnicity, and symptomatic for a median of 6 days prior to baseline. There was no statistically significant benefit of remdesivir at 14 days in terms of mortality or clinical status; there were signals of effectiveness in time-to-recovery after day 9, and a reduction in 28-day mortality. <h4>Conclusion</h4> In a real-world setting, initiation of remdesivir within 24h of hospitalisation in conjunction with standard of care was not associated with a benefit at 14 days but supports clinical trial evidence of a potential reduction in 28-day mortality.
| Item Type: | Preprint |
|---|---|
| Uncontrolled Keywords: | 32 Biomedical and Clinical Sciences, 3202 Clinical Sciences, Coronaviruses, Comparative Effectiveness Research, Clinical Research, Coronaviruses Therapeutics and Interventions, Emerging Infectious Diseases, Health Disparities and Racial or Ethnic Minority Health Research, Health Disparities, Infectious Diseases, Clinical Trials and Supportive Activities, Biodefense, 3 Good Health and Well Being |
| Divisions: | Faculty of Health & Life Sciences Faculty of Health & Life Sciences > Clinical Directorate Faculty of Health & Life Sciences > Inst. Infection, Vet & Ecological Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 24 Jun 2021 08:01 |
| Last Modified: | 26 Feb 2026 19:49 |
| DOI: | 10.1101/2021.06.18.21259072 |
| Open Access URL: | https://www.medrxiv.org/content/10.1101/2021.06.18... |
| Related Websites: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3127439 |
| Disclaimer: | The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate. |
Altmetric
Altmetric